DOT Prohibits CBD Use

Cannabidiol (CBD) is a nonpsychoactive chemical compound extracted from the cannabis plant. Typically found in oil form, CBD is used to treat a variety of medical issues such as inflammation, epileptic seizures, and anxiety.

CBD is chemically distinguishable from THC, and therefore will not cause a positive drug test result under the DOT drug testing panel. However, as the manufacturing and purification processes for CBD products are unregulated, it is possible for CBD products to contain other cannabinoids, such as THC.

The Drug Enforcement Agency recently created an extremely limited exception for CBD formulations that include no more than 0. I percent THC, moving FDA-approved medicinal formulations to Schedule V of the Controlled Substances Act.

However, only one medication, is prescribed for two rare epilepsy disorders—is currently available.

All other cannabis products, including CBD, are classified as Schedule I controlled substances under the Controlled Substances Act and, thus, are illegal under federal law. 49 CFR Part 40 does not authorize the use of Schedule I drugs for any reason.

As always, your EAP Reps are available to address any questions or concerns.

 AFA International  1-800-424-2406 or your local EAP 503-729-4439.